New radiation approach targets tough pancreatic tumors
NCT ID NCT03505229
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests stereotactic body radiotherapy (SBRT), a precise, high-dose radiation given over 2 weeks, for people with high-risk localized pancreatic cancer. The goal is to see if it can stop the tumor from growing locally for at least 12 months. The trial includes 30 participants who have already had or will have chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Stereotactic body radiotherapy (SBRT)
- What this could lead to
- If successful, SBRT could offer a more precise, shorter radiation option to control pancreatic cancer locally, potentially improving outcomes for patients with high-risk disease.
- What could go wrong
- This is a small, early-phase study (30 people) with no control group, so results may not apply broadly. SBRT also carries risks of radiation side effects to nearby organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Dec 2018
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 86 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 and able to give informed consent * Patients with histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas, including patients with extrapancreatic extension (Stage IIA), node positive (Stage IIB), borderline resectable or locally advanced as defined by AGITG guidelines * ECOG performance status 0-1 * Measurable disease as defined by RECIST 1.1 * Have received or plan to receive chemotherapy * Successful insertion of fiducial markers Exclusion Criteria: * Patients with metastatic pancreas cancer * Prior abdominal radiotherapy * Active malignancy excluding non melanomatous skin cancer * Neuroendocrine pancreatic carcinoma * Pregnant or lactating women * Tumour size greater then 70mm * Age \>85
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High risk localised pancreatic adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia